Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 10/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31091444 | 0.94 | FTO (0.44) | FTOMEN1MAPTHTTKMT2A | |
| SCHEMBL3146789 | 0.90 | FTO (0.45) | FTOMEN1MAPTHTTKMT2A | |
| SCHEMBL2859711 | 0.90 | FTO (0.42) | FTOMEN1MAPTHTTKMT2A | |
| SCHEMBL29358769 | 0.90 | FTO (0.45) | FTOMEN1MAPTHTTKMT2A | |
| SCHEMBL4323243 | 0.83 | FTO (0.47) | FTOMEN1MAPTHTTKMT2A | |
| SCHEMBL4318993 | 0.83 | FTO (0.43) | FTOMEN1MAPTHTTKMT2A | |
| SCHEMBL30105431 | 0.83 | FTO (0.46) | FTOMEN1MAPTHTTKMT2A | |
| SCHEMBL3685151 | 0.82 | MEN1 (0.40) | FTOMEN1MAPTHTTKMT2A | |
| SCHEMBL3685707 | 0.82 | FTO (0.43) | FTOMEN1MAPTHTTKMT2A | |
| SCHEMBL3688575 | 0.80 | FTO (0.42) | FTOMEN1MAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12571798-B2 | Cancer biomarkers and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-10 | — | — | US | disclosed |
| US-12332245-B2 | Cancer biomarkers and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-06-17 | — | — | US | disclosed |
| EP-3941630-B1 | PRECISE DELIVERY OF COMPONENTS INTO FLUIDS | CELLULAR RES INC (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2024-10-03 | — | — | US | disclosed |
| US-20240263165-A1 | Precise Delivery of Components into Fluids | BECTON, DICKINSON AND COMPANY | 2024-08-08 | — | — | US | disclosed |
| US-11976269-B2 | Precise delivery of components into fluids | CELLULAR RESEARCH, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-11965208-B2 | Methods of associating phenotypical data and single cell sequencing data | BECTON, DICKINSON AND COMPANY (US) | 2024-04-23 | — | — | US | disclosed |
| CN-113557090-B | Accurate delivery of components into a fluid | 赛卢拉研究公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-3796002-B1 | CANCER BIOMARKERS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230204591-A1 | CANCER BIOMARKERS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-29 | — | — | US | disclosed |
| EP-3884935-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-114404588-A | Compounds and methods for inhibiting phosphate transport | 阿德利克斯公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3941630-A1 | PRECISE DELIVERY OF COMPONENTS INTO FLUIDS | Cellular Research, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12571798-B2 | Cancer biomarkers and methods of use thereof | MKI67, BRCA1, CD68 | FTO 4236/4885MEN1 4354/4885MAPT 2345/4885 |
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | FTO 4008/4885MEN1 2203/4885MAPT 4468/4885 |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | SLC34A3, SLC34A2, SLC34A1 | FTO 4008/4885MEN1 2203/4885MAPT 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.